Iptacopan

Overview

Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC 50 value of 10 nM and K D of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G).

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Complement System

Product Information

• Catalog No.: HY-127105
• CAS No.: 1644670-37-0
• Molecular Formula: C25H30N2O4
• Molecular Weight: 422.52
• Purity: 99.95%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 5 mg/mL (11.83 mM); Clear solution
• Availability: In-stock

Source

Original product source